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INTRODUCTION
Blood coagulation factor XIII (FXIII, also called fibrin-
stabilizing factor) is a transglutaminase that plays an impor-
tant role in clot stabilization by crosslinking fibrin chains
(1). FXIII exists in a tetrameric form consisting of two cat-
alytic A-subunits (FXIIIA) and two carrier protein B-sub-
units (FXIIIB) that are held together by non-covalent bond-
ings and weigh approximately 320 kDa (2, 3). While FXIII-
As clearly have the catalytic activity, FXIIIBs are thought to
protect FXIIIAs from proteolysis and stabilize their structure
(4). FXIII has a pivotal role in the coagulation process. Cross-
linked stable fibrin contributes to the resistance to chemical,
mechanical, and proteolytic insults.
The gene coding for FXIIIA maps to chromosome 6p24-
25, encodes a mature protein of 731 amino acids (5, 6), and
spans altogether over 160 kb. It contains 15 exons (6) that
code for a 4-kb mRNA (7). FXIIIB is comprised of 641 amino
acids with 10 tandem repeats of 60 amino acids each and its
coding region has been assigned to chromosome 1q31-32
(8). Only three mutations have been reported in the gene of
FXIIIA (9-11), and two mutations in the gene of FXIIIB (12).
Both genes exhibit common protein polymorphisms among
various population groups (13, 14).
There is an increasing interest in the role of FXIII in car-
diovascular and cerebrovascular diseases. It has been previ-
ously reported that a common G→T point mutation in exon
2, codon 34 of the FXIIIA gene, which elicicts a valine-to-
leucine change (FXIII Val34Leu), is protective against throm-
botic disease, but seems to increase the risk of intracerebral
bleeding.
Surprisingly, the less frequent allele (Leu34) does not in-
crease the risk of thrombosis, but has been described as being a
protective factor against myocardial infarction (15, 16), brain
infarction (17), and deep vein thrombosis (18, 19). On the
other hand, there seems to be an increased risk for intracere-
bral hemorrhage (15, 20). Regarding the prevalence, FXIII
Val34Leu was shown to be highly prevalent in Caucasians,
but a very low prevalence in Japanese (21).
To our knowledge, there has been no report on the preva-
lence of FXIII Val34Leu in Koreans. In this study, we inves-
tigated the distribution of FXIII Val34Leu, and then evalu-
ated the relationship between the polymorphism and primary
intracerebral hemorrhage in Korean population using PCR-
SSCP method and gene sequencing.
MATERIALS AND METHODS
Subjects
Fifty-eight patients with primary intracerebral hemorrhage
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No Association of Factor XIII Val34Leu Polymorphism with Primary
Intracerebral Hemorrhage and Healthy Controls in Korean Population
The polymorphism in the factor XIII A-subunit gene (FXIII Val34Leu) has been
recognized as a risk factor for primary intracerebral hemorrhage (PICH). In addi-
tion, FXIII Val34Leu has a significant ethnic heterogeneity. FXIII Val34Leu was
detected in 41.7-54.8% of the Westerners, but in 2.5% of the Asians. We aimed
to evaluate the prevalence of FXIII Val34Leu in patients with PICH and in healthy
controls among Koreans. We recruited 58 in-patients with PICH, defined by brain
computed tomography or magnetic resonance imaging, and 48 controls matched
for age, sex, and risk factors for cerebrovascular diseases. Genomic DNA was
extracted from blood. A 183-bp fragment of exon 2/intron B of the factor XIII A-
subunit gene was amplified by polymerase chain reaction (PCR). The factor XIII
genotype was determined through a single-stranded conformational polymorphism.
Fifty-eight patients and 48 controls showed the same band patterns on SSCP.
In addition, we directly sequenced six random-selected DNA segments using
DNA auto-sequencer. In conclusion, the results of this study suggest that FXIII
Val34Leu be absent or rare both in patients with PICH and in healthy controls
among Koreans. 
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(PICH) admitted to the Department of Neurology at Chon-
nam National University Hospital were prospectively recruit-
ed between April 1999 and April 2000. Diagnosis of PICH
was verified by computed tomography (CT) or magnetic res-
onance imaging (MRI) in each patient on admission, within
24 hr from the onset of symptoms. Exclusion criteria were
1) subarachnoid hemorrhage, 2) bleeding tendency disorders,
3) history of previous cerebrovascular accidents or recent trau-
ma, 4) history of other neurological disorders and 5) intrac-
erebral hemorrhage (ICH) caused by congenital vascular mal-
formation. During the same period, we selected 48 healthy
control subjects from those visiting to the health screening
center. They had no history of vascular, thromboembolic, or
hemorrhagic disease, or ongoing antithrombotic therapy. They
were also matched for age, sex, and selected risk factors for
arterial thromboembolic disease (smoking history, hyperten-
sion, cholesterol level and diabetes) with the respective pa-
tient. All subjects gave informed consent.
Analysis of ICH
Hemorrhage volumes were measured by a simplified for-
mula for the volume of an ellipsoid, ABC/2 (22). For the bed-
side ABC/2 method, the CT slice with the largest area of
hemorrhage was identified. The largest diameter (A) of the
ICH was measured on this slice. Then the largest diameter
90° to A was measured next (B) on the same slice. Finally,
the approximate number of 1 cm slices containing the ICH
was calculated (C). C was calculated by comparison of each
CT slice with hemorrhage to the CT slice with the largest
hemorrhage on that scan.
Classification of each hematoma was based on the location
of the epicenter of the hematoma as basal ganglia, lobar (front-
al, parietal, temporal, or occipital), thalamus, cerebellum,
brain stem, or other (combined with ventricle).
Extraction of DNA from venous blood
Peripheral blood (3 mL) was anticoagulated with 1.6 mg/
mL EDTA. Genomic DNA was extracted from 100  L venous
blood using the Dr. GenTLETM kit (TaKaRa Shuzo Co., Ltd,
Japan).
DNA amplification by polymerase chain reaction (PCR)
A 183-bp fragment of exon 2/intron B of the factor XIII
gene was amplified by the polymerase chain reaction (PCR),
with 5′ -ACCCAGAGTGGTGGGGAAG as a 5′ primer and
5′ -GACCTTGTAAAGTCAAAAATGTC as a 3′ primer.
The DNA extract was amplified by PCR in 50  L of reac-
tion mixture containing 2  L (200 ng) of DNA extracts, 5
L of 10×reaction buffer, 6  L of 1.5 mM MgCl2, 0.5  L
of Taq DNA polymerase (TaKaRa), 4  L of 2.5  M dNTP,
1  L (50 pmol) of each primer, and 30.5  L of sterilized dis-
tilled water. The reaction samples were preheated at 94℃for
5 min; then, they were subjected to cycling of denaturation
for 1 min at 94℃, annealing for 1 min at 55℃, and elon-
gation for 2 min at 72℃ for 35 cycles; this was followed by
post-elongation reaction at 72℃ for 2 min in a GeneAmp
PCR system 9600 (Perkin Elmer Co., Norwalk, CT, U.S.A.).
After the reaction, electrophoresis of the mixture containing
5  L of post-PCR solution and 2  L of loading buffer (0.25%
bromophenol blue/0.25% xylene cyanol/50% glycerol) was
performed on 1.8% polyacrylamide gel that contained 1  g/
mL of ethidium bromide. DNA bands were identified through
ultraviolet transilluminator.
Single-stranded conformational polymorphism (SSCP)
analysis and identification of the Factor XIII Val34Leu
genotype
To detect the substitution of thymine to guanine (Val34Leu),
we performed the single-stranded conformational polymor-
phism (SSCP) analysis on the PCR products. Five microliters
of the PCR product was mixed with 1  L of alkaline dena-
turing solution containing 0.2 M NaOH and 20 mM EDTA,
4  L of sterilized distilled water, and SSCP loading buffer.
The samples were heated at 95℃ for 6 min, cooled briefly
on ice, and loaded onto a 20% TBE Gel (5:1 TBE/bisacry-
lamide ratio; NOVEXTM). Electrophoresis was run for 9 hr
at room temperature (14-18℃) at 8 W constant power in
0.5×TBE running buffer. During the electrophoresis, per-
formed in a renaturating condition, the DNA fragments
undergo conformational changes according to their base se-
quence. The migration in the electrical field depends on the
size and conformation of the DNA fragment, so that an aber-
rant migration is usually detected both in deletions/insertions
and single-base substitutions. The gel was subjected to SYBR
�
Green II staining for 20 to 40 min. The bands were identi-
fied through FLARE 3000 (image pro).
The PCR product was further purified by a QIAquick gel
extraction kit (Qiagen, Germany), and was inserted into a
PGEM T easy vector and directly sequenced using dye-labeled
terminators (ABI Prism
� BigDyeTM Terminator Cycle Sequen-
cing Ready Reaction Kits version 2.0, Perkin-Elmer) on an
ABI Prism 377 DNA Sequencer. We confirmed the geno-
types of 183 bp-fragments by sequencing randomly selected
6 samples (3 patients with PICH and 3 healthy controls).
RESULTS
Characteristics of the study population
Table 1 summarizes the relevant general characteristics of
the patients. Detailed information concerning the presence
of major risk factors for cerebrovascular disease (hypertension,
dyslipidemia, diabetes, obesity, and smoking) was availableFactor XIII Val34Leu Polymorphism 251
for patients and controls. No significant differences were found
in the prevalence of selected risk factors for cardiovascular
disease between patients and controls. Of the 58 patients
evaluated, the mean volume (cm3) of hematoma was 20.07
(range: 0.13-81.39). The most common site of ICH was
basal ganglia (29.3%). Genomic DNA from venous blood
was available in all cases (n=58) and controls (n=48).
Identification of FXIII 183-bp fragments on electropho-
resis after PCR
After PCR amplification of 183-bp fragments, DNA bands
were identified through ultraviolet transilluminator, and
photographed (Fig. 1). The PCR products of the patients
were indistinguishable from those of the healthy controls on
the agarose gel, suggesting that no major deletion or inser-
tion in that exon area was responsible for the disease.
Screening for mutations in the XIIIA gene by PCR-SSCP
and DNA sequencing
To screen mutations of the A-subunit gene of FXIII, the
genomic DNA from patients and healthy controls were ana-
lyzed by PCR-SSCP. The conditions for SSCP analysis were
optimized by limiting the size of the PCR products and by
varying the buffer and glycerol concentrations for electropho-
resis. No mobility difference was detected between the pa-
tients and healthy controls on SSCP (Fig. 2). 
To confirm the presence of a point mutation, the PCR prod-
ucts were subjected to direct sequencing analysis, which re-
vealed no mutations in FXIII exon2/intronB in patients with
ICH and in control. This demonstrates the absence of a com-
mon G→T point mutation in exon 2, codon 34 of the FXIII-
A gene.
DISCUSSION
Genetic polymorphism of FXIII subunits was first report-
ed by Board (23). Following studies demonstrated the exis-
tence of several allelic variants of FXIII-A with a wide dis-
tribution among racial groups. Data from gene, cDNA, and
protein sequencing revealed several amino acid substitutions
in apparently normal subjects. One of the common polymor-
phisms is a G→T point mutation in codon 34, exon 2 of the
A-subunit gene, which codes for a Valine→ Leucine change
(FXIII Val34Leu) only three amino acids apart from the
Groups
Age (yr)
Patients with PICH Healthy controls
Male (n) Female (n) Total (n) Male (n) Female (n) Total (n)
30-39 1 0 1 1 0 1
40-49 5 4 9 4 3 7
50-59 7 6 13 6 6 12
60-69 14 10 24 13 8 21
70-79 3 5 8 2 3 5
>80 2 1 3 1 1 2
Total 32 26 58 27 21 48
Mean±SD (yr) 58.8±9.8 63.3±12.1 60.9±11.1 59.2±8.7 62.9±11.8 60.8±10.6
Table 1. The characteristics of patients with primary intracerebral hemorrhage (PICH) and healthy controls
Fig. 1. Identification of 183 bp segment of Factor XIII A-chain
cDNA. The electrophoresed PCR products were visualized by
ethidium bromide staining. Lane M, DNA molecular size mark-
ers for 100 bp; Lanes P1-8, DNA from patients with ICH; Lanes
C1-8, DNA from healthy controls.




Fig. 2. Analysis of the Val34Leu point mutation in exon2/intron B
of the factor XIII A subunit gene by single-stranded conforma-
tional polymorphisms (SSCP). The figure shows the genotype
pattern obtained by SSCP. SSCP of 183 bp segment of the fac-
tor XIII A subunit gene reveals no variant mobility shifts. Lanes
p1-7, DNA from patients with ICH; lanes c1-7, DNA from healthy
controls.
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thrombin activation site (15, 24). Because of this proximity,
this polymorphism might well influence the process of pro-
teolytic activation and is therefore a candidate for a role in
the pathogenesis of thrombotic disorders.
The role of common polymorphism of FXIII Val34Leu has
been recently recognized as a protective genetic factor against
arterial and venous thrombosis. In addition, the less frequent
Leu34 allele has been described as a risk factor for ICH. The
FXIII Val34Leu has been recently reported to confer protec-
tion against arterial and venous thrombosis (15-19, 25, 26)
and predisposition to PICH (20, 27), although not all stud-
ies report its protective role against ischemic diseases (20,
28, 29). How FXIII Val34Leu protects against thrombosis
and predisposes to hemorrhage are not completely understood,
but it seems that owing to an early activation, a premature
depletion of the circulating FXIII Leu34 is a protective effect
against thrombosis (30, 31). FXIII Val34Leu may be respon-
sible for the formation of weaker fibrin structures through a
common mechanism for protection against myocardial is-
chemia or cerebral infarction and predisposition to PICH.
Genetic polymorphisms underlie the diversity of any ethnic
group. Most of such inherited changes in DNA structure are
neutral, but others could affect the function of proteins and,
with varying degrees of severity, the efficiency of a whole phy-
siological system, thus modifying susceptibility to a particu-
lar disease.
The FXIII Val34Leu polymorphism was originally de-
scribed in a Finnish population composed of 600 controls
with a allele frequency of 23% (24), similar to that in other
study population (15) and in small groups of Finnish, Rus-
sian, German, and Japanese subjects (32). Renner et al. (26)
found a prevalence of 26.2% heterozygous and 7.8% homozy-
gous carriers of FXIII Val34Leu among controls in Austria.
McCormack et al. (33) reported that Asians, Caucasians, and
Pima Indian groups had different leucine allele frequencies
(0.13, 0.28, and 0.40, respectively). The Leu allele seems to
be less common in Japanese than in the three Caucasian po-
pulations (32).
Reported allele frequencies of FXIII Val34Leu range from
0.25 to 0.30, with 32% to 43% heterozygous, and 4% to
10% homozygous carriers (16, 18, 19, 34). Recently, FXIII
Val34Leu was detected in 44.3% of Caucasians, 28.9% of
Blacks, 2.5% of Asians, and 51.2% of Amerindians (21).
However, limited data are available about the prevalence of
the FXIII Val34Leu among Asians. To our knowledge, there
has been no information on the exact prevalence of FXIII
Val34Leu polymorphism in Koreans until now.
Our results are in line with those of previous studies that
showed FXIII Val34Leu was absent or had a very low preva-
lence among Japanese (35), and then demonstrate that FXIII
Val34Leu is also rare in Korean population. The high preva-
lence of FXIII Val34Leu in Caucasians and a very low preva-
lence of that in Koreans and Japanese, imply a heterogeneous
distribution of the polymorphism. Taken together, our data
showed that FXIII Val34Leu exhibits a significant ethnic
heterogeneity, a finding that is relevant to studies relating
this polymorphism with thrombotic and bleeding disorders.
On the other hand, three points should be borne in mind
when interpreting our results. First, the number of our sub-
jects was too small. Second, our study might have false neg-
ative results because we could not carry out the direct sequence
of 183 bp segment of Factor XIII A-chain cDNA in all sub-
jects. Third, our study was performed in a limited area (Chon-
nam Province).
However, these results should facilitate future investiga-
tions to identify genetic variations in clotting factor genes
that play a role in the risk for cerebrovascular diseases. We
suggest that further studies with larger numbers of partici-
pants should be performed.
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